perpetuity. It is made available under a CC-BY 4.0 International license .

1 Antimicrobial agents for the treatment of enteric

² fever chronic carriage: A systematic review

- 3 Short title: Antimicrobial agents for the treatment of enteric fever
- 4 chronic carriage

5 McCann N^{1,2}, Scott P^{1,2}, Parry CM^{3,4,5}, Brown M^{,1,6}

- 7 1. Hospital for Tropical Diseases, University College London Hospitals NHS
- 8 Foundation Trust, London, UK
- 9 2. UCL Faculty of Population Health Sciences, University College London
- 10 (UCL), London, UK
- 11 3. Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
- 12 4. Alder Hey Children's NHS Foundation Trust. Liverpool, UK
- 5. Centre for Tropical Medicine and Global Health, University of Oxford, Oxford,
 UK.
- 15 6. Clinical Research Dept, London School of Hygiene & Tropical Medicine
- 16

6

- 17
- 18
- 19
- 20 Correspondence to:
- 21 Dr Naina McCann,
- 22 <u>Naina.mccann@nhs.n</u>et/zchaf30@ucl.ac.uk
- 23

24 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26 Background

Chronic carriage of *S*. Typhi or *S*. Paratyphi is an important source of enteric
fever transmission. Existing guidance and treatment options for this condition
are limited. This systematic review aims to assess the evidence concerning the
efficacy of different antimicrobials in treating enteric fever chronic carriage.

31

32 Methods

33 We searched major bibliographic databases using relevant keywords between 34 1946 and September 2021. We included all interventional studies that included 35 patients with confirmed enteric fever chronic carriage and deployed an 36 antimicrobial that remains in clinical practice today. Case reports and case series 37 of under 10 patients were excluded. Two reviewers screened abstracts, selected 38 articles for final inclusion and quality-assessed the included studies for risk of 39 bias. Extracted data was analysed, with pooling of data and eradication rates for 40 each antimicrobial calculated. As only one randomised controlled trial was 41 identified no meta-analysis was performed.

42

43 **Results**

Of the 593 papers identified by the initial search, a total of eight studies met the
inclusion criteria and were included in the systematic review. Evidence was
identified for the use of fluoroquinolones and amoxicillin/ampicillin in the
treatment for enteric fever chronic carriage. Fluoroquinolones were superior to
amoxicillin/ampicillin with 92% of patients eradicated after one antimicrobial

49 course compared to 68% (p = 0.02). The quality of included studies was poor,
50 and all were carried out before 1990.

51

52 Conclusion

53 This review identified fluoroquinolones and amoxicillin as treatment options for

54 enteric fever chronic carriage, with fluoroquinolones the more effective option.

55 However, this evidence pre-dates rises in antimicrobial resistance in enteric

56 fever and therefore the significance of these findings to today's practice is

57 unclear. Further research is needed to investigate whether these antimicrobials

remain appropriate treatment options or whether alternative interventions aremore effective.

60

61

62 Author summary

63 There are more than 14 million cases of enteric fever every year globally. The 64 rise of antimicrobial resistance against *S*. Typhi and *S*. Paratyphi, the pathogens 65 causing enteric fever, has led to limited treatment options against this condition. 66 Mechanisms to prevent infection are therefore becoming increasingly important. 67 Public health measures and, more recently, the development and rollout of the 68 typhoid conjugate vaccine, are going some way towards reducing transmission of 69 this condition but identification and treatment of enteric fever chronic carriers 70 has been neglected.

72	S. Typhi and S. Paratyphi are restricted to human hosts and transmitted via the
73	ingestion of contaminated food or water. Chronic carriers, those who
74	asymptomatically excrete the pathogens in their stool following infection, play
75	an important role in maintaining the reservoir of infection within humans.
76	Identification and treatment of these carriers will be vital in further reducing
77	transmission of enteric fever and ultimately eliminating this condition.
78	
79	Here we review the evidence for antimicrobials in treating enteric fever chronic
80	carriage. We identify evidence for fluoroquinolones and amoxicillin as treatment
81	strategies but highlight large gaps in the literature on this subject, including a
82	lack of evidence in the antimicrobial-resistant era of enteric fever.
83	

84 Introduction

85

86	Enteric fever is a systemic febrile illness caused by infection with the Gram-
87	negative bacteria Salmonella enterica subspecies serovars Typhi (S. Typhi) and
88	Paratyphi A, B or C (S. Paratyphi). It causes significant morbidity and mortality
89	globally, with approximately 14 million cases and 135,000 deaths per year, with
90	the highest number of reported cases from South and South-East Asia(1).
91	
92	Enteric fever is transmitted via the faecal-oral route via the ingestion of food or
93	water contaminated with infected human faeces. Clinical illness usually occurs 7-
94	14 days after exposure with a non-specific febrile illness. The majority of
95	patients recover from acute enteric fever following an appropriate course of

96 antimicrobials. Around 10% of patients continue to excrete S. Typhi or S. 97 Paratyphi in their stool for a few weeks in the convalescent period following 98 recovery from acute infection with approximately 1-5% of patients continuing to 99 excrete S. Typhi or S. Paratyphi in their stool for more than one year (2,3). This 100 latter group are known as chronic carriers(4). 101 102 The pathogenesis of chronic carriage is not well understood. The gallbladder and 103 biliary system appear to be the site of primary persistence of *S*. Typhi and *S*. 104 Paratyphi in chronic carriers and indeed those with gallstones are more likely to 105 become carriers (4–6). 106 107 S. Typhi and S. Paratyphi are human-restricted pathogens and therefore chronic 108 carriage plays an important role in maintaining the reservoir of infection in 109 humans. Asymptomatic chronic carriers unknowingly transmit the disease to 110 others by faecal contamination of food and water. The first, and perhaps most 111 famous example of this was Mary Mallon ('typhoid Mary') who worked as a chef 112 in New York in the 1950s and infected at least 54 people as an asymptomatic 113 carrier(3). Since then forensic epidemiology has demonstrated many more such 114 cases, for example Mr N the Folkestone milker who infected over 200 people 115 over a number of years via infected milk (7). 116 117 In addition to the public health risk of chronic carriage there is evidence that 118 chronic carriage is associated with an increased individual risk of malignancy, 119 particularly gallbladder cancer (8–10). A recent meta-analysis reported an

overall odds ratio of gallbladder cancer in *S.* Typhi carriers of 4.28 (95% CI:
1.84–9.96) (11).

122

123	The identification and treatment of chronic carriers therefore has both a
124	significant public health and arguably individual benefit. There is currently
125	limited evidence or guidance on how these chronic carriers should be treated.
126	Furthermore, recent clinical reviews on the subject give differing advice on
127	whether antimicrobials are an effective treatment option for chronic carriage
128	treatment (12–14).
129	
130	WHO enteric fever guidelines from 2003 suggest treatment options for enteric
131	fever chronic carriage of amoxicillin, co-trimoxazole or ciprofloxacin (15). Over
132	the last 30 years there have been significant changes in antimicrobial resistance
133	patterns of <i>S.</i> Typhi and <i>S.</i> Paratyphi, with decreased susceptibility to
134	fluoroquinolones (Fq) now almost universal in some areas of South Asia and
135	increasing across sub-Saharan Africa (16–18). Multi-drug resistance (MDR),
136	resistance to amoxicillin, co-trimoxazole, chloramphenicol, is also seen in around
137	40% of patients worldwide (16). A current outbreak of extensively-drug-
138	resistant (XDR) enteric fever in Pakistan has highlighted the limited
139	antimicrobial treatment options available for acute enteric fever in this setting.
140	The options for antimicrobial treatment of enteric fever chronic carriers in the
141	era of drug-resistance are unknown.
142	
143	The aim of this systematic review is to review the existing evidence of efficacy of

144 antimicrobials in treating enteric fever chronic carriage. By doing so we hope to

145 review existing knowledge and highlight areas for ongoing research and review.

146

147 Methods

- 148 The reporting of this systematic review was guided by the standards of the
- 149 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
- 150 statement (19). A search of PROSPERO database performed did not reveal any
- 151 existing similar protocols. The protocol for this review was not registered but
- 152 can be found in supplementary material (S3)
- 153

154 Search strategy and selection criteria

- 155 A systematic search through MEDLINE, EMBASE and Web of Science from 1946
- 156 was initially performed on the 1st February 2021. The terms searched were
- 157 ("typhoid" OR "paratyphoid" OR "salmonella typhi" OR "salmonella paratyphi
- 158 "OR "enteric fever") AND
- 159 ("chronic carriage" OR "disease carrier "OR "carrier state" OR "typhoid carrier"
- 160 OR "paratyphoid carrier" AND
- 161 ("antibiotic" OR "antibacterial" OR "antibacterial treatment" OR "antibiotic
- 162 treatment" OR "antibacterial agent" OR "antibiotic agent" OR names of individual
- antibiotics). The full list of search terms is listed in the supplementary
- 164 information (S1). No language restrictions were included in the initial search.
- 165 Reference lists and bibliographies of selected articles were also searched. A
- 166 search for unpublished literature was not performed.

168	A repeat search of the same terms was performed in September 2021 to check								
169	for any additional studies that could be included prior to publication. All new								
170	articles identified that been published since the prior search date were reviewed								
171	by two independent reviewers.								
172									
173	We included studies that met the following criteria:								
174	1) Baseline population of adults with confirmed enteric fever chronic								
175	carriage								
176	2) Intervention of an antimicrobial course								
177	3) Outcomes of stool clearance measured as defined by authors of each								
178	included study								
179									
180	We did not include studies that assessed an antimicrobial that is no longer in								
181	clinical use today, for example sulphathiazole. Case reports and case series of								
182	under 10 cases were excluded to minimize study bias. If studies included								
183	participants with non-typhoidal salmonella (NTS) chronic carriage in addition to								
184	patients with enteric fever chronic carriage these studies were individually								
185	reviewed to assess whether they included 10 or more patients with enteric fever								
186	chronic carriage and, if they met other inclusion criteria, they were included.								
187	Studies that combined an antimicrobial treatment intervention with another								
188	intervention (e.g. cholecystectomy) were only included if they had an								
189	intervention arm that included antimicrobials alone and this was made up of \geq								
190	10 patients.								
101									

- 192 If journal articles were not available online, we requested print versions through
- 193 store requests in our academic institution. Articles were excluded if we could not
- 194 access a full-text version for review. Two independent researchers screened
- titles and abstracts and reviewed full text articles for inclusion with any
- 196 disagreements resolved by consensus.
- 197

198 Quality of studies

- 199 Two independent reviewers evaluated the study quality with any disagreements
- 200 resolved by consensus. Quality assessment was performed using the National
- 201 Heart, Lung and Blood Institute quality assessment tools (20). Each study was
- 202 given an overall rating of good, fair or poor.

203

204 Data extraction

- 205 Data extraction was performed using a standardized data extraction form. Data
- 206 was collected on publication year, study country, study design, participant
- 207 characteristics including number of patients with gallstones, number of
- 208 participants given intervention, intervention type including dose and duration,
- stool culture result at follow-up and side effects of intervention.
- 210

211 Data analysis

- 212 For each included study the proportion of those chronic carriers that eradicated
- 213 the pathogen (eradication proportion) was calculated (i.e., the number of
- 214 participants culture negative for *S*. Typhi or *S*. Paratyphi after an antimicrobial
- intervention divided by the total number of participants in the study).

216

217	For those that had a control population we calculated the eradication proportion
218	in this population. Data was synthesized for studies using the same antimicrobial
219	intervention and overall eradication proportions presented. The main outcome
220	measure was eradication proportion after one course of antimicrobials. As some
221	studies re-treated their patients' multiple times, we also calculated eradication
222	proportion per antimicrobial course. Other data synthesised for each
223	antimicrobial intervention included intervention characterises and side effects of
224	antimicrobial use. Results were presented in tabular format comparing
225	antimicrobial intervention. Categorical variables were compared using Fishers
226	exact test. Data was collated in Microsoft Excel and analysed in RStudio version
227	1.4.1103.
228	
229	

230 **Results**

231

232 Flow of included studies

233 The initial search strategy identified 579 papers. The abstracts and titles were

reviewed and after applying inclusion and exclusion criteria 26 papers were

235 identified for full-text evaluation. Of these a further 18 were excluded for reasons

- shown in the PRISMA flow-chart in Figure 1, leaving 8 articles which met our
- 237 inclusion criteria. Full-text manuscripts could not be accessed in 7 cases; all but
- one of these were published in non-English language journals (3 German, 1
- 239 Polish, 1 Russian, 1 Japanese). Of these 3 were published before 1960 and the

- remaining 4 were published before 1980. A further search using the same terms
- was performed in September 2021 which identified a further 14 papers, none of
- 242 which were deemed eligible for inclusion.

243

- **Figure 1**. Preferred Reporting Items for Systematic Reviews (PRISMA) flow
- 245 diagram of the study selection process

246

247 Study characteristics

- 248 Study characteristics of all included studies are summarised in Table 1. Only one
- used a blinded randomised-control trial (RCT) design. The remaining seven
- studies used an open, pre- post design method with no controls, comparing stool
- culture (outcome measure) in participants before and after treatment.
- 252
- 253 Included studies were carried out between 1966 and 1988, with no studies
- included from the last 30 years. The majority of studies were carried out in the
- USA (n= 4) with the remaining papers conducted in Chile (n = 1), Peru (n = 1),
- 256 Italy (n=1) and Israel (n=1).

257

258 Table 1. Summary of included studies

Study author	Country	Year	Journal	Planned	Study design	01
and references			published	intervention, drug,		
				dose and duration		

Ferreccio et al	Chile	1988	Journal of	Ciprofloxacin PO	Open pre- and post- trial,	3
(21)			Infectious	750mg BD, 28 days	no control	3,
			Diseases			tr
Gotuzzo et	Peru	1988	Journal of	Norfloxacin PO	Double-blind randomised-	St
al(22)			Infectious	400mg BD, 28 days	controlled trial, followed by	1,
			Diseases		open trial	
Phillips et al	USA	1971	Journal of	Ampicillin PO 1g	Open pre- and post- trial,	St
(23)			American	QDS, 90 days	no control	m
			Medical			tr
			Association			
Simon et al (24)	USA	1966	New England	Ampicillin PO 75-	Open pre- and post- trial,	St
			Journal of	100mg/kg/day for	no control	fi
			Medicine	28 days		fo
						ti
						7
Nolan et al (25)	USA	1978	Journal of	Amoxicillin PO 2g	Open pre- and post- trial,	St
			American	TDS for 28 days	no control	m
			Medical			
			Association			
Dinbar et al	Israel	1969	American	Ampicillin PO	Open, multi-arm pre- and	St
(26)			Journal of	5.25mg/day for 10-	post- trial, no control	m
			Medicine	40 days		tr
Kaye et al (27)	USA	1967	Annals of the	Ampicillin PO 1.5mg	Open pre- and post- trial,	St
			New York	QDS + probenecid	no control	de
			Academy of	0.5g QDS, 42 days		m
			Science			

Scioli et al (28)	Italy	1970	Journal of	Ampicillin IV 1g TDS,	Open pre- and post- trial,	Ste
			Infectious	15 days	no control	foi
			Diseases			on
						of

200	
261	Inclusion criteria for almost all the studies was presence of <i>S</i> . Typhi or <i>S</i> .
262	Paratyphi in the stool or bile for greater than 12 months. One study necessitated
263	prior history of acute enteric fever (29) and one study included two patients who
264	had positive stool cultures with an elevated Vi antibody level, without need for
265	repeated positive cultures of > 1 year (30). One study mentioned that included
266	patients had been previously treated for chronic carriage (28) but others did not
267	specify this. Length of chronic carriage varied between participants within
268	studies, with the longest carrier state being 39 years. Two studies excluded those
269	with serious underlying health conditions and patients with penicillin allergies
270	(29,31). Exclusion criteria were not well defined in the other studies.
271	
272	The age range of included participants was broad, including adults from 18-81
273	years. One study included one child aged 7 years old with the results not
274	separated from the 14 adults in the study(32). After discussion between
275	reviewers this study was included. The majority of participants in the studies
276	were female which correlates with prior knowledge that females are more likely
277	to be carriers (33).

Most of the studies investigated participants for underlying gallstones before
enrolment in the study using ultrasound or cholangiography or X-ray. However,
in some patients the biliary tract was not well visualised and two studies did not
investigate for underlying gallstones prior to enrolment (30,34). These patients
were categorised in a third category 'gallstone status unknown'.

284

285 Study intervention

286 The intervention drug was a fluoroquinolone (Fq) in two studies: norfloxacin

287 was used in one and ciprofloxacin in the other. Four of the studies used

ampicillin alone as the intervention, one study used amoxicillin and one used

ampicillin with probenecid. One of the ampicillin studies used intravenous

administration but the rest of the studies used oral administration. Dosing varied

between the different studies (see Table 1). One study also included separate

arms of the study with patients undergoing cholecystectomy and

cholecystectomy in combination with ampicillin treatment (26). In this study six

of the patients undergoing antimicrobial treatment alone had previously

295 undergone cholecystectomy in the other arm of the study. These were included

as they were confirmed to still be chronic carriers 1 year post cholecystectomy

and prior to enrolment in the antimicrobial arm.

298

299 **Quality assessment**

300 Overall methodological quality of included studies was poor (see Table 1). There

301 was only one randomised and blinded study, with the majority of studies

302 designed as pre- and post-studies without a control.

303 In the RCT study, the outcomes were inconsistently reported with the summary 304 table showing no cases of eradication in the placebo group but the text reporting 305 that one patient this arm did have negative stool cultures at follow-up (indicating 306 spontaneous cure). Furthermore, 13 patients were enrolled in the norfloxacin 307 arm but only 12 patients included in the final analysis with no intention-to-treat 308 analysis performed. No relative risk or odds ratio was calculated. 309 The remainder of the studies were open, pre- and post- studies without controls. 310 311 Overall inclusion criteria were well defined, but studies did not clearly state how 312 patients were enrolled. 313 314 Interventions were generally well defined but often not consistent across 315 participants, with some studies changing dosing regimens during the study 316 period and one study using multiple interventions on participants (26). All 317 studies clearly defined the outcome measure, and this was measured before and after intervention and at repeated intervals for adequate follow-up periods after 318 319 intervention. Loss to follow-up in the included studies was small (less than 20% 320 in all). None of the studies mentioned a power calculation and numbers of 321 participants were small in all studies. Minimal statistical analysis was performed. 322 323 A meta-analysis was not performed as there was only one RCT identified. 324 **Outcomes by antimicrobial group** 325 Fluoroquinolones 326

327	Two studies as	ssessed Fa as a	a treatment of	ntion for S. T	'vphi ch	nronic carria	ige, and
	I wo beauteb a	556556a i q ub t	a ci cucificile o		y pin ci		ige, and

- 328 no studies assessed Fq as a treatment option for *S.* Paratyphi chronic carriage. In
- 329 the *S*. Typhi studies a total of 25 patients received an intervention course
- 330 (29,35). The norfloxacin study was an RCT, comparing 28-days of 400mg BD
- 331 norfloxacin to placebo. The ciprofloxacin study was a pre-post study
- investigating the effect of a 28-day course of 750mg BD ciprofloxacin. All patients
- had *S.* Typhi chronic carriage, 44% of whom were known to have gallstones
- (although this was not specifically looked for in one of the studies). Both Fq
- studies showed an eradication proportion of 92% following a single 28-day
- treatment course. These two studies are summarised in Table 2.
- 337
- 338 **Table 2. Summary of results from studies using fluoroquinolone antibiotics**
- 339 to treat S. Typhi chronic carriage

medRxiv preprint doi: https://doi.org/10.1101/2021.11.09.21266081; this version zoosted November 9, Ferret in preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

picpinit (thick had not continue by poor forming in a data p It is/medvention/given	erpetuity. a NoPfloxalci e	rna piaaeelis er	nseCiprofloxacin	
	n	0		
Participant characteristics				
Total no of participants, n	13	12	12	25
With gallstones, n (%)	9 (69)	9 (75)	2 (17)	11 (44)
Without gallstones, n (%)	4 (31)	3 (25)	0	4 (16)
Unknown gallstone status, n (%)	0 (0)	0	10 (75)	10 (36)
Demographics				
Age, mean	36	35	31	34
Age, range	18-58	12-67	20-51	18-67
Female, n (%)	6 (46)	11	10 (83)	16 (64)
		(92)		
Microbiological characteristics				
S. Typhi, n (%)	13 (100)	12	12 (100)	25 (100)
		(100)		
MIC to intervention drug, range (ug/mL)	0.06 – 0.5	0.06-	0.0156-0.0078	0.0078-0.5
		0.5		
Intervention				
Administration method	РО	РО	PO	
Total daily dose, mean (mg)	800	NA	1500	
Total duration, mean (days)	28	28	25	
Duration range, (days)	28	28	10-28	
Outcomes – eradication				
Minimum follow-up (months)	3	3	12	3
Total no of patients included in analysis ¹ , n	12	12	12	24
Total no patients eradicated at end of follow-up, n (%)	11 (92)	1 (8)	11 (92)	22 (92)
Eradicated in those with gallstones, n (%)	7 (88)	1 (8)	2 (100)	9 (82)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.09.21266081; this version posted November 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Eradicated in those without gallstones, n (%) 4 (100) 0(0)0(0)4 (100) 9 (90) Eradicated in those with unknown gallstone status, n (%) 0(0) 0(0) 9 (90) *Outcomes – side effects* 1(8) 3 (25) 5 (41) 6 (25) Total side effects, n (%) 0 0 Diarrhoea, n (%) 0 0 Rash, n (%) 0 0 1(8) 1(4) Other, n (%) 1(8) 3 (25) 4 (33) 5 (21) Total no of antibiotic courses given², n 23 12 12 35

18 (78)

1(8)

11 (90)

29 (83)

No of antibiotic courses resulting in successful eradication, n (%)

340 1 - One patient was excluded from norfloxacin analysis in Gottuzo paper due poor adherence
341 2 - In Gotuzzo paper 10 placebo patients were re-treated with norfloxacin openly taking the total
342 number of treatment courses given in this paper to 23.
343
344 In the RCT the norfloxacin group had a higher proportion of *S.* Typhi eradication

345 than the control group (92% vs 8%, p <0.001).

346

347 Effect of gallstones on eradication

348 Patients in the ciprofloxacin study were not routinely screened for biliary

349 disease before enrolment in the study, however two patients were known to

350 have gallstones. In the norfloxacin study patients underwent oral

351 cholecystogram, IV cholangiography or gallbladder ultrasound before enrolment.

352

Eradication proportions were 100% in those without gallstones, 89% in those

with unknown gallstone status and 82% in those with known gallstones.

355

356 Side effects

357 Side effects were seen in a quarter of patients. In the ciprofloxacin study two

358 patients stopped treatment early due to side effects (haemoglobin drop and

- 359 urticarial rash). Of note, three other patients in this study had a haemoglobin
- drop that were attributed to ciprofloxacin therapy. Norfloxacin was relatively
- 361 well-tolerated in the other study with only one patient reporting a rash, although
- these are not further explored in this paper.
- 363

364 *Effect of repeated courses*

- 365 In the norfloxacin study patients initially treated with placebo were then
- 366 retreated with norfloxacin. This group had a slightly lower eradication
- 367 proportion of 70%, lowering the overall eradication proportion to 83% per
- antibiotic course overall.
- 369

370 Ampicillin/amoxicillin

- 371 The remaining six studies identified assessed amoxicillin or ampicillin
- 372 (amox/amp) use. The results of these are summarized in Table 3.
- 373
- 374 **Table 3. Summary of results from studies using amoxicillin or ampicillin as**
- 375 a treatment for S. Typhi or S. Paratyphi chronic carriage

medRxiv preprint doi: https://doi.org/10.1101/2021.11.09.212660 Phillips ersion pos Sighton /ember 9, 2 Molain e copyrigh Dielber for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in								
Participdvit ofnakoeteivistiksu	perpetuity. der a CC-BY 4.0 Ir	nternational license						
Total no of participants	12	15	15	16	24			
With gallstones, n (%)	0	5 (33)	4 (27)	3 (12)	12 (50)			
Without gallstones, n (%)	0	10 (66)	11 (73)	7 (87)	7 (25)			
Unknown gallstone status, n (%)	12 (100)	0 (0)	0 (0)	6 (38)	5 (21)			
Known to have had cholecystectomy, n (%)	0 (0)	1 (7)	0	7 (44)	1 (4)			
Demographics								
Age, mean	57	44	65	53	59			
Age, range	23-81	7-62	48-77	36-67	33-83			
Female, n (%)	7 (58)	10 (66)	13 (87)	7 (44)	18 (75)			
Microbiological characteristics								
S. Typhi, n (%)	12 (100)	15 (100)	12 (100)	15 (94)	24 (100)			
MIC to intervention drug, range (ug/mL)	NA	<1 - 2	< 1	0.5-2.5	NA			
Intervention characteristics								
Intervention name	Ampicillin	Ampicillin	Amoxicillin	Ampicillin	Ampicillin			
Administration method	РО	РО	РО	РО	РО			
Intended daily regimen	1g QDS	75-	2g TDS	1.25g QDS	1.5g QDS			
		100mg/kg						
Intended duration (day)	90	28	28	10-40	42			
Addition of probenecid	No	No	No	No	Yes			
Dosing details of initial course given								
Total daily dose, mean (g)	4	4	5.2	5.1	5.5			
Total course duration, mean (days)	90	28	28	25	36			
Total dose taken during course, mean (g)	360	112	146	128	198			
Outcomes – eradication								
Minimum follow-up (months)	18	7	12	12	12			
Total no patients eradicated after initial course, n (%)	9 (75)	13 (87)	11 (73)	7 (44)	9 (38)			

Eradicated in those with gallstones, n (%)	0 (0)	4 (80)	3 (75)	0 (0)	4 (33)
Eradicated in those without gallstones, n (%)	0 (0)	8 (89)	9 (82)	4 (57)	5 (71)
Eradicated in those with unknown gallstone status, n (%)	9 (75)	0 (0)	0 (0)	3 (50)	0 (0)
Eradicated in those with known cholecystectomy, n (%)	0 (0)	1 (100)	0 (0)	3 (43)	0 (0)
Total no of patients eradicated at end of follow-up, n (%)	9 (75)	13 (87)	11 (92)	9 (56)	12 (50)
Total no of antibiotic courses given, n	12	17	15	21	31
No of antibiotic courses resulting in successful eradication (%)	9 (75)	13 (76)	11 (73)	9 (43)	12 (39)
Outcomes – side effects					
Total side effects, n (%)	8 (67)	10 (67)	7 (47)	NA	5 (21)
Diarrhoea, n (%)	5 (42)	8 (53)	3 (20)		1 (4)
Rash, n (%)	5 (42)	6 (40)	2 (13)		5 (21)
Anaphylaxis	1 (9)				
Other, n (%)	0 (0)	2 (20)	3 (20)		

376

377

378

Overall, 101 patients were given a total of 115 courses of amox/amp (either PO

or IV). Most of these patients were female and 28% had confirmed gallstones.

381 Only one patient had *S*. Paratyphi. The dosing regimens were relatively high with

the mean daily dose of amoxicillin 4.5g/day but this varied significantly between

383 studies (range 3-5.5g/day). The mean duration of treatment was 37 days but

again this was highly variable between regimens (range 15-90 days).

385

The overall eradication proportion after a single course of amox/amp was 68%

but again, this was highly variable between studies (range 38-100%).

388

389 Effect of administration method on eradication

There was only one study looking at the effect of IV ampicillin on chronic
carriage eradication proportion(28). The mean daily dose and total cumulative
dose of IV ampicillin used in this study were much lower than those used in the
oral studies (3g vs a mean of 4.7g for the oral studies). However, the eradication
proportion in this study was notably higher when compared to the oral
ampicillin studies (100% vs 60%, p <0.01) with no failures described in the IV
arm.

398 Effect of dosing regimen and duration on eradication

The total daily dose of amox/amp varied between 4 and 5.5g for the studies

400 using oral intervention, with the total drug given over the duration of the course

401 between 112g to 360g.

402

403 Overall comparisons between dosing regimen and duration are not possible as

404 different studies used widely variable dosing regimens and durations, often not

405 standardised within their own study population. Therefore, individual regimens

406 within studies were examined more closely to investigate for possible

407 associations of dosing or duration with outcome.

408

409 In the Nolan et al study (36) two different dosing regimens of amoxicillin were

410 given. For those that tolerated it (n = 10) a dosing regimen of 2g of oral

411 ampicillin was administered three times daily (total daily dose of 6g) which had

a 90% success after one course of 28 days. In those who did not tolerate the

413 higher dose (n= 5) a lower dosing regimen of 1g oral ampicillin three times a day

414 (total daily dose of 3 grams) was started. This regimen only had a 40%

415 eradication proportion after 28 days, but the numbers were very small.

416


417 Similarly, in Phillips et al (23) those who completed the full dosing schedule had

418 a 90% eradication proportion whereas those who were unable to complete it

419 had a 0% eradication proportion, although these numbers are small and the

420 exact dosing regimens are not fully described in the paper.

421



423 ampicillin given over this time. This regimen had an eradication proportion of

424 38%. Over the period of the study the dose of ampicillin was increased to 200g

425 given over 40 days. The eradication proportion of this regimen was 57%. There

426 was no evidence to support a difference in eradication proportions between

427 dosing regimens (p = 0.61).

428

429 The Kaye study was the only study to use probenecid in addition to ampicillin.

430 Eradication proportions were lower in this study when compared to the other

431 studies where probenecid was not used (38% vs 76%).

432

Overall, we are unable to draw any firm conclusions from this data whether dose
or duration of this intervention effects eradication proportion although there is a
slight suggestion that higher daily dosing and intravenous dosing may be slightly
more effective.

437

438 Effect of gallstones on eradication

439 All studies investigated for prior presence of gallstones except Phillips et al.

440 The eradication proportion was lower in those with gallstones compared to

those without gallstones (55% vs 79%, p = 0.039). Those with unknown

442 gallstone status had an eradication proportion of 62%, whereas those with a past

443 cholecystectomy only had an eradication proportion of 50%, although the

444 numbers in this group are small.

445

446 *Effect of repeated courses on eradication*

447 After failing an initial course of therapy some patients were re-treated with a

second or third course. In Kaye et al six patients who failed an initial course were

re-treated with further courses of ampicillin. Of these only two were successfully

450 eradicated (27). In Dinbar et al four patients who initially failed therapy were

451 successfully treated with higher dosing regimens of ampicillin (26). In Simon et

al one patient was re-treated twice with prolonged six-week courses of

453 ampicillin which did not result in eradication (24). In total, of the 11 patients that

454 were re-treated, the eradication proportion was only 36%.

455

456 Side effects

457 A third of patients in the ampicillin studies suffered side effects from their

therapy. Rash and diarrhoea were the most common side effects and in two

studies this resulted in a modification to therapy (31,34). In the IV amoxicillin

trial side effects were minimal. However, side effects were not routinely

461 reported across the studies.

462

463 **Comparing antimicrobial groups**

- 464 Fluoroquinolones have a higher overall eradication proportion than amox/amp
- 465 (92% vs 68%, p = 0.02). In those with gallstones the eradication proportion
- 466 remains higher in those taking a Fq compared to those taking amox/amp but this
- 467 is not significant (82% vs 55%, p = 0.16).
- 468
- 469

470 **Discussion**

- 471 This is the first systematic review on the efficacy of antimicrobial agents for
- treatment of enteric fever chronic carriage. A total of 126 participants in 8
- 473 studies were included in this review and two intervention groups were
- identified: Fq and amox/amp. Overall eradication proportion was higher in the
- Fq compared to the amox/amp group (92% vs 68%, p = 0.02), but eradication
- 476 proportions varied highly across the included studies.
- 477
- 478 These findings are consistent with the limited existing guidelines available on
- treatment of chronic carriage. As previously stated, the only available guidance
- 480 for treatment of chronic carriers is from the WHO 2003 guidelines which
- 481 suggests a quinolone, amoxicillin or co-trimoxazole (12,15). In this review we
- 482 have not identified any specific evidence for use of co-trimoxazole. During the
- 483 screening process we did identify literature investigating the use of co-
- 484 trimoxazole in addition to other antimicrobials such as chloramphenicol,
- 485 kanamycin and penicillin (37–43). None of these studies met the criteria for
- 486 inclusion in this study, again highlighting the poor quality of available evidence

487 on this subject. Most of these studies were case reports, small case series or did 488 not report on necessary outcome data.

489

490	The findings of this systematic review should be interpreted with caution.
491	Firstly, the overall quality of the included studies was poor, with only one RCT
492	included. The remainder of the studies were case series or pre- and post- studies
493	with no control group and no blinding, which allowed for significant bias.
494	Furthermore, in most studies it was unclear how patients had been identified for
495	participation. Interventions were non-consistent within and across studies and
496	the total number of included patients is small, limiting statistical analysis and
497	overall conclusions.
497 498	overall conclusions.
	overall conclusions. Secondly, almost all the patients included in this study had <i>S</i> . Typhi chronic
498	
498 499	Secondly, almost all the patients included in this study had <i>S</i> . Typhi chronic
498 499 500	Secondly, almost all the patients included in this study had <i>S</i> . Typhi chronic carriage and therefore limited conclusions can be made about the effectiveness

504 currently no licensed vaccine for S. Paratyphi the role of treatment of carriers of

- 505 this condition may become increasingly important in reducing enteric fever
- 506 transmission and disease. This review identifies current large gaps in the

507 evidence base for the treatment of this neglected condition.

508

509 Thirdly, and perhaps most importantly, the included trials were all carried out

- 510 prior to widespread antimicrobial resistance of enteric fever. There are no
- 511 studies that have been carried out to assess treatment options for enteric fever

chronic carriage in patients with multi-drug resistant (MDR), Fq-resistant, or
indeed extensively-drug-resistant enteric fever. This data is therefore inadequate
to inform decisions regarding antimicrobial treatment of chronic carriage in the

- 515 modern-day era of drug-resistant enteric fever.
- 516

517 Further research needs be done to understand and improve treatment options 518 for enteric fever chronic carriers today. The first barrier to investigating 519 treatment interventions on chronic carriers is the accurate identification of 520 chronic carriers from the population. In the trials included in this study, regular 521 stool cultures were used to identify carriers over many years. This is logistically 522 challenging and not suitable for large-scale screening today, particularly in low-523 resource endemic areas. Furthermore, as stool shedding is intermittent, the 524 sensitivity is low (45). Molecular and serological strategies to identify carriers 525 have been explored but do not perform well, particularly in endemic settings 526 (46,47). New methods to identify carriers such as antigen-specific antibodies and 527 biomarkers show promise but need further exploration (48,49).

528

529 Once carriers can be accurately identified, further work is needed to investigate 530 the effect of different interventions on this population. There is limited data on 531 the antimicrobial susceptibility of chronic carriage isolates and whether they 532 harbour similar resistance profiles to acute enteric fever strains. A study from 533 2012 in Nepal looking at *S*. Typhi and *S*. Paratyphi isolates identified from 534 cholecystectomies found lower rates of antimicrobial resistance in these strains, 535 compared to acute enteric fever isolates in the same area (50). This suggests that 536 chronic carriage strains may originate from older, drug-susceptible strains for

537 which Fq and Amp may still be effective. Previous work looking at the genetic

538 diversity of S. Typhi has suggested this may be due to two different evolutionary

methods within the population structure of S. Typhi (51).

540

541 Even if chronic carriage isolates do show reduced susceptibility to ciprofloxacin,

the excellent bile penetration of this antimicrobial (reaching 2500-4500% of

543 plasma concentrations in the bile(52)), may be sufficient to overcome the

relatively low minimum inhibitory concentration (MIC) (e.g. with MIC \leq 1)

isolates, although there is no patient outcome data to support this.

546

547 Alternative antimicrobials that have not been identified in this review may also

548 be effective in treating chronic carriage. Azithromycin is currently used to treat

uncomplicated enteric fever worldwide with good efficacy (53) but no studies

550 have examined the efficacy of azithromycin on enteric fever chronic carriage.

551 Azithromycin has good bile penetration (52) and a single case report suggests it

may eradicate non-typhoidal *Salmonella* carriage (54). It therefore may be a

553 good intervention for enteric fever chronic carriage treatment and is currently

the preferred treatment for Fq resistant chronic carriage eradication in the UK;

555 post-treatment monitoring will be used to assess outcome.

556

557 It is well understood that the gallbladder is an important niche for the

persistence of *S.* Typhi and *S.* Paratyphi and the development of carriage (12,55).

559 Accordingly, cholecystectomy has been used as treatment for chronic carriage in

the past (26,56,57). In addition to carrying a significant anaesthetic and surgical

risk this intervention does not guarantee elimination of the carrier state, with

562	success rates reported between 70-90%. Studies in this review also identify
563	multiple patients identified as carriers who had already undergone a prior
564	cholecystectomy. Hence, it is likely that there are other foci of infection outside
565	the gallbladder that also play an important role in <i>S.</i> Typhi and <i>S</i> . Paratyphi
566	persistence and carriage, for example the biliary tree, liver or lymph nodes(58).
567	
568	Recently, murine models have shown that biofilm formation, on gallbladder
569	epithelium and cholesterol-rich gallstones, may play an important role in the
570	development of carriage and protect against antimicrobial treatment (55,59–63).
571	Prior guidance similarly states that carriers with underlying gallstones are
572	unlikely to be eradicated with antimicrobials alone (12,15). In contrast, this
573	review shows relatively good eradication proportions in those with gallstones,
574	particularly when Fq treatment was used, albeit lower than those without
575	gallstones. Furthermore, many of the identified carriers in this review were not
576	found to have gallstones, despite thorough investigation. It is evident that further
577	work is required to better understand the pathophysiology of chronic carriage to
578	allow the development of targeted interventions.
579	

580 This review was limited by the high risk of bias in all included studies. Many 581 studies showed selection bias with undefined selection of participants and 582 exclusion of certain groups. The participants may not be a true representative of 583 the carrier population. Minimal data was reported from all studies with very 584 little statistical analysis performed. Particularly, the presence of gallstones was 585 not investigated or reported in all studies meaning conclusions on whether 586 gallstones affect the effect of antimicrobial eradication are uncertain.

587

588	Side effects of medications were also poorly reported across studies. Some
589	adverse events were linked to the intervention without obvious causality e.g.
590	ciprofloxacin causing haemoglobin drop, when this is not a known common side
591	effect. Furthermore, associations of Fq therapy that were not recognised when
592	these studies took place, for example tendinopathy and aneurysm rupture, may
593	have been under-reported. The recent realisation of potential significant side
594	effects of Fq use has also led to restrictions in their use and they may no longer
595	be suitable to treat patients with chronic carriage, again highlighting the need for
596	alternative treatment strategies (64,65).
597	
598	In this review we excluded case reports or case series of less than 10 patients in
599	attempt to reduce bias but in doing so may have excluded studies with additional
600	interventions. Furthermore, the evidence relating to this topic is almost all more
604	

601 than 30 years old and some full-text articles were not able to be accessed, some

602 of which may have otherwise been included in the final review. The strengths of

603 our study include a comprehensive search strategy, the use of two independent

reviewers throughout the process and the use of well-defined data extraction

605 and quality assessment tools.

606

In conclusion, this review identifies evidence for fluoroquinolones and
amoxicillin/ampicillin as antimicrobial interventions for treatment of enteric
fever chronic carriage. Fluoroquinolones are the most effective antimicrobial
intervention and should be recommended for first-line treatment of chronic
carriage where the isolate is susceptible, given the lack of evidence for any other

- 612 interventions. There is insufficient evidence to recommend empiric use of
- 613 fluoroquinolones or amoxicillin/ampicillin for enteric fever chronic carriage
- today, due to significant changes in antimicrobial resistance over the last 30
- 615 years. Updated evidence on this neglected topic is required and should be a vital
- 616 component of global eradication strategies for enteric fever going forward.
- 617
- 618

619 **References**

020		
621 622 623 624 625	1.	Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis [Internet]. 2019 Apr 1 [cited 2021 Mar 17];19(4):369–81. Available from: http://dx.doi.org/10.1016/
626 627 628 629	2.	T.M. V. Temporary and chronic carriers of Salmonella typhi and Salmonella paratyphi B. J Hyg (Lond) [Internet]. 1948;(3):252–61. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&N EWS=N&AN=280592805
630 631 632	3.	Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of the gall bladder by Salmonella Typhi: Understanding the carrier state. Nat Rev Microbiol. 2011;
633 634 635	4.	Levine MM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of salmonella typhi in santiago, chile, an endemic area. J Infect Dis. 1982;
636 637	5.	Vogelsang TM, Bøe J. Temporary and chronic carriers of Salmonella typhi and Salmonella paratyphi B. J Hyg (Lond). 1948;
638 639	6.	Ames WR, Saphir W, Baer WH, Plotke F. Treatment of typhoid carriers. J Am Med Assoc. 1942;119:582.
640 641	7.	Mortimer PP. Mr N the milker, and Dr Koch's concept of the healthy carrier. Vol. 353, Lancet. Elsevier; 1999. p. 1354–6.
642 643	8.	Caygill CPJ, Hill MJ, Braddick M, Sharp JCM. Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet. 1994;
644 645	9.	Nath G, Singh H, Shukla VK. Chronic typhoid carriage and carcinoma of the gallbladder. European Journal of Cancer Prevention. 1997.
646 647 648	10.	Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol. 2000;
649 650	11.	Nagaraja V, Eslick GD. Systematic review with meta-analysis: The relationship between chronic Salmonella typhi carrier status and gall-
651 652	12.	bladder cancer. Alimentary Pharmacology and Therapeutics. 2014. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. Salmonella

653		chronic carriage: Epidemiology, diagnosis, and gallbladder persistence
654		[Internet]. Vol. 22, Trends in Microbiology. Elsevier Ltd; 2014 [cited 2021
655	10	Mar 17]. p. 648–55. Available from: /pmc/articles/PMC4252485/
656	13.	Gal-Mor O. Persistent infection and long-term carriage of typhoidal and
657		nontyphoidal salmonellae. Clinical Microbiology Reviews. 2019.
658	14.	Parry CM, Hein TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. New
659		England Journal of Medicine. 2002.
660	15.	World Health Organization WHO Background document: The diagnosis,
661		treatment and prevention of typhoid fever Communicable Disease
662		Surveillance and Response Vaccines and Biologicals [Internet]. 2003 [cited
663	1.6	2021 Feb 23]. Available from: www.who.int/vaccines-documents/
664	16.	Browne AJ, Kashef Hamadani BH, Kumaran EAP, Rao P, Longbottom J,
665		Harriss E, et al. Drug-resistant enteric fever worldwide, 1990 to 2018: A
666		systematic review and meta-analysis. BMC Med [Internet]. 2020 Jan 3
667		[cited 2021 Mar 17];18(1):1–22. Available from:
668	4 🗖	https://doi.org/10.1186/s12916-019-1443-1
669	17.	C. B. Screening, phylogenetic analysis and antibiotic sensitivity pattern of
670		Salmonella enterica serovar Typhi isolates from typhoid asymptomatic
671		carriers. Asian Pac J Trop Med [Internet]. 2011;4(10):769–72. Available
672		from:
673		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&
674	10	NEWS=N&AN=362795595
675 676	18.	Qamar FN, Yousafzai MT, Sultana S, Baig A, Shakoor S, Hirani F, et al. A
676		Retrospective Study of Laboratory-Based Enteric Fever Surveillance,
677 678		Pakistan, 2012–2014. J Infect Dis [Internet]. 2018 Nov 10 [cited 2021 Mar 17];218(suppl_4):S201–5. Available from:
679		https://academic.oup.com/jid/article/218/suppl_4/S201/5060309
680	19.	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et
681	17.	al. The PRISMA 2020 statement: An updated guideline for reporting
682		systematic reviews. The BMJ. 2021.
683	20.	Study Quality Assessment Tools NHLBI, NIH [Internet]. [cited 2021 Mar
684	20.	29]. Available from: https://www.nhlbi.nih.gov/health-topics/study-
685		quality-assessment-tools
686	21.	C. F, J.G. MJ, C. V, I. P, V. S, G.L. D, et al. Efficacy of ciprofloxacin in the
687		treatment of chronic typhoid carriers. J Infect Dis [Internet].
688		1988;157(6):1235–9. Available from:
689		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N
690		EWS=N&AN=18164989
691	22.	E. G, J.G. G, L. B, J.C. P, C. C, J. L, et al. Use of norfloxacin to treat chronic
692		typhoid carriers. J Infect Dis [Internet]. 1988;157(6):1221–5. Available
693		from:
694		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N
695		EWS=N&AN=18164987
696	23.	Treatment of chronic typhoid carriers with ampicillin. JAMA [Internet].
697		1971;217(7):913–5. Available from:
698		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N
699		EWS=N&AN=91440054
700	24.	Simon HJ, Miller RC. Ampicillin in the Treatment of Chronic Typhoid
701		Carriers. N Engl J Med. 1966;


702	25.	NOLAN CM, ROSENFELD J. ANTIBIOTIC SUSCEPTIBILITY OF
703		SALMONELLA-TYPHI FROM CHRONIC ENTERIC CARRIERS. Curr Ther Res
704		Exp. 1977;21(5):736–40.
705	26.	Dinbar A, Altmann G, Tulcinsky DB. The treatment of chronic biliary
706	27	Salmonella carriers. Am J Med. 1969;
707	27.	Kaye D, Merselis JGJ, Connolly S, Hook EW. Treatment of chronic enteric
708 709		carriers of Salmonella typhosa with ampicillin. Ann N Y Acad Sci [Internet]. 1967;145(2):429–35. Available from:
709		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE
711		WS=N&AN=5284273
712	28.	Scioli C, Fiorentino F, Sasso G. Treatment of Salmonella typhi carriers with
713		intravenous ampicillin. J Infect Dis [Internet]. 1972;125(2):170–3.
714		Available from:
715		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE
716		WS=N&AN=5007553
717	29.	Gotuzzo E, Guerra JG, Benavente L, Palomino JC, Carrillo C, Lopera J, et al.
718		Use of norfloxacin to treat chronic typhoid carriers. J Infect Dis [Internet].
719		1988;157(6):1221–5. Available from:
720 721		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N EWS=N&AN=18164987
721	30.	C. F, J.G. MJ, C. V, I. P, V. S, G.L. D, et al. Efficacy of ciprofloxacin in the
723	50.	treatment of chronic typhoid carriers. J Infect Dis [Internet].
724		1988;157(6):1235–9. Available from:
725		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N
726		EWS=N&AN=18164989
727	31.	C.M. N, Nolan CM, White PC. Treatment of typhoid carriers with
728		amoxicillin. Correlates of successful therapy. J Am Med Assoc [Internet].
729		1978;239(22):2352–4. Available from:
730		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&N
731	22	EWS=N&AN=8388271
732 733	32.	Simon HJ, Miller RC. Ampicillin in the treatment of chronic typhoid carriers. Report on fifteen treated cases and a review of the literature. N
734		Engl J Med [Internet]. 1966;274(15):807–15. Available from:
735		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE
736		WS=N&AN=5908876
737	33.	Ames WR, Robins M. Age and Sex as Factors in the Development of the
738		Typhoid Carrier State, and a Method for Estimating Carrier Prevalence. Am
739		J Public Heal Nations Heal. 1943;
740	34.	Treatment of chronic typhoid carriers with ampicillin. JAMA (Chicago, Ill)
741		[Internet]. 1971;217(7):913–5. Available from:
742		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&N
743	25	EWS=N&AN=292051214
744 745	35.	C. F, J.G. MJ, C. V, I. P, V. S, G.L. D. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J Infect Dis [Internet]. 1988;157(6):1235–9.
745 746		Available from:
747		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed4&N
748		EWS=N&AN=18164989
749	36.	Nolan CM, White PC. Treatment of Typhoid Carriers With Amoxicillin:
750		Correlates of Successful Therapy. JAMA J Am Med Assoc. 1978;


751	37.	H. P, H. K, K.H. S, G. V. Treatment of chronic carriers of Salmonella typhi
752		and Salmonella paratyphi B with trimethoprim sulfamethoxazole. J Infect
753		Dis. 1973;
754	38.	Tauchnitz C, Horn M, Forster E. [Treatment of S. typhi and S. paratyphi B
755		carriers]. Zur Sanierung von Typhus- und Paratyphus-B-
756		Dauerausscheidern [Internet]. 1972;27(15):647–54. Available from:
757		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE
758		WS=N&AN=4485581
759	39.	Brodie J, Macqueen IA, Livingstone D. Effect of Trimethoprim-
760		Sulphamethoxazole on Typhoid and Salmonella Carriers. Br Med J. 1970;
761	40.	CROCKER TT, GELPERIN A, Th.T. C. Treatment of the typhoid carrier state
762		with chloramphenicol. Yale J Biol Med [Internet]. 1950;23(2):119–24.
763		Available from:
764		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emcl1&N
765		EWS=N&AN=280603709
766	41.	C.A. R, RUMBULL CA, MOORE LG, C.A. R, RUMBALL CA, MOORE LG, et al.
767		Treatment of a chronic typhoid carrier with chloromycetin. Br Med J
768		[Internet]. 1949;1(4612):943. Available from:
769		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N
770		EWS=N&AN=608414974
771	42.	T.E. W, J.E. S, WOODWARD TE, SMADEL JE, LEY HLJ, T.E. W, et al.
772		Chloramphenicol and other antibiotics in the treatment of typhoid fever
773		and typhoid carriers. J Clin Invest [Internet]. 1950;29(1):87–99. Available
774		from:
775		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med1&NE
776		WS=N&AN=15399518
777	43.	A.M. G, R.N. P. Treatment and follow-up studies with co-trimoxazole in
778		enteric fever and in typhoid carriers. J Antimicrob Chemother [Internet].
779		1975;1(1):51–4. Available from:
780		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed2&N
781		EWS=N&AN=5551869
782	44.	Dong B-Q, Yang J, Wang X-Y, Gong J, von Seidlein L, Wang M-L, et al. Trends
783		and disease burden of enteric fever in Guangxi province, China, 1994–
784		2004. Bull World Health Organ. 2010;
785	45.	BOKKENHEUSER V. DETECTION OF TYPHOID CARRIERS. American
786		journal of public health and the nation's health. 1964.
787	46.	Nath G, Maurya P, Gulati AK, Singh TB, Srivastava R, Kumar K, et al.
788		Comparison of Vi serology and nested PCR in diagnosis of chronic typhoid
789		carriers in two different study populations in typhoid endemic area of
790		India. Southeast Asian J Trop Med Public Health. 2010;
791	47.	Gupta A, My Thanh NT, Olsen SJ, Sivapalasingam S, My Trinh TT, Phuong
792		Lan NT, et al. Evaluation of community-based serologic screening for
793		identification of chronic Salmonella Typhi carriers in Vietnam. Int J Infect
794		Dis. 2006 Jul 1;10(4):309–14.
795	48.	Charles RC, Sultana T, Alam MM, Yu Y, Wu-Freeman Y, Bufano MK, et al.
796		Identification of Immunogenic Salmonella enterica Serotype Typhi
797		Antigens Expressed in Chronic Biliary Carriers of S. Typhi in Kathmandu,
798		Nepal. PLoS Negl Trop Dis [Internet]. 2013 [cited 2021 Mar 29];7(8).
799		Available from: https://pubmed.ncbi.nlm.nih.gov/23936575/

800	49.	Franklin F, Chong CW, Chua LH, Anthony AA, Liew MWO, Aziah I, et al.
801		Evaluation of Salmonella Typhi antigen YncE alongside HlyE for the
802		detection of typhoid fever and its carriers. Med Microbiol Immunol. 2020;
803	50.	D. C, J. M, D. K, C.M. H, J.L. S, J.A. K, et al. Drug resistance in Salmonella
804		enterica serotype Typhi isolated from chronic typhoid carriers. Clin Infect
805		Dis [Internet]. 2015;12(1):536–8. Available from:
806		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed1&N
807		EWS=N&AN=4495214
	۲1	
808	51.	P. R, FX. W, C. D, S. BBB, S. BBB, T.C. N, et al. Evolutionary history of
809		Salmonella Typhi. Science (80-) [Internet]. 2006;314(5803):1301–4.
810		Available from: http://www.sciencemag.org
811	52.	Gilbert Davi, Chambers Henry, Saag Michael PA. Sanford Guide to
812		Antimicrobial Therapy 2020. Sanford Guide to Antimicrobial Therapy
813		2020. 2020.
814	53.	Effa EE, Bukirwa H. Azithromycin for treating uncomplicated typhoid and
815		paratyphoid fever (enteric fever) [Internet]. Cochrane Database of
816		Systematic Reviews. John Wiley and Sons Ltd; 2008 [cited 2021 Mar 29].
817		Available from: https://pubmed.ncbi.nlm.nih.gov/18843701/
818	54.	Imbert P, Rapp C, Lecoules S, Garrabe E, Debord T. Eradication of
819	54.	multiresistant Salmonella Hadar convalescent-phase carriage with
820		azithromycin. Clin Microbiol Infect. 2003 Nov;9(11):1155–6.
821	55.	Gonzalez-Escobedo G, Marshall JM, Gunn JS, G. G-E, J.M. M, Gonzalez-
822		Escobedo G, et al. Chronic and acute infection of the gall bladder by
823		Salmonella Typhi: Understanding the carrier state. Nat Rev Microbiol
824		[Internet]. 2011;9(1):9–14. Available from:
825		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&
826		NEWS=N&AN=51172587
827	56.	Vogelsang TM. The campaign against typhoid and paratyphoid B in
828		western Norway. Results of cholecystectomy. J Hyg (Lond). 1964;
829	57.	Main RG. Treatment of the chronic alimentary enteric carrier. Br Med J.
830		1961;
831	58.	Nath G, Pratap CB, Patel SK, Gulati AK, Tripathi SK. Isolation of Salmonella
832	50.	typhi from apparently healthy liver. Infect Genet Evol. 2011;
833	59.	J. M, D. K, C.M. H, J.L. S, J.A. K, J.R. F, et al. Identification of a Small Molecule
	59.	
834		Anti-biofilm Agent Against Salmonella enterica. Front Microbiol [Internet].
835		2018;9(NOV):2804. Available from:
836		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=prem&NE
837		WS=N&AN=30515144
838	60.	Prouty AM, Schwesinger WH, Gunn JS, A.M. P, W.H. S, Prouty AM, et al.
839		Biofilm formation and interaction with the surfaces of gallstones by
840		Salmonella spp. Infect Immun [Internet]. 2002;70(5):2640–9. Available
841		from:
842		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed7&N
843		EWS=N&AN=34408410
844	61.	Crawford RW, Rosales-Reyes R, Ramírez-Aguilar MDLL, Chapa-Azuela O,
845	01.	Alpuche-Aranda C, Gunn JS. Gallstones play a significant role in Salmonella
846	()	spp. gallbladder colonization and carriage. Proc Natl Acad Sci U S A. 2010;
847	62.	J.F. G, H. A, J. L, L. D, Gonzalez JF, Alberts H, et al. Biofilm Formation
848		Protects Salmonella from the Antibiotic Ciprofloxacin In Vitro and In Vivo

849 850 851 852		in the Mouse Model of chronic Carriage. Sci Rep [Internet]. 2018;8(1):222. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med15&N EWS=N&AN=29317704
853	63.	Adcox HE, Vasicek EM, Dwivedi V, Hoang K V, Turner J, Gunn JS, et al.
854		Salmonella extracellular matrix components influence biofilm formation
855		and gallbladder colonization. Infect Immun [Internet]. 2016;84(11):3243–
856		51. Available from:
857		http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med13&N
858		EWS=N&AN=27600501
859	64.	Persson R, Jick S. Clinical implications of the association between
860		fluoroquinolones and tendon rupture: The magnitude of the effect with
861		and without corticosteroids. Br J Clin Pharmacol. 2019;
862	65.	Raine J. Fluoroquinolone antibiotics: New restrictions and precautions due
863		to very rare reports of disabling and potentially long-lasting or irreversible
864		side effects. Medicines & Healthcare products Regulatory Agency. 2019.
865		
866		
867	Suj	pporting Information
868		

- 869 **S1. PRISMA Checklist**
- 870 S2. Search strategy
- 871 **S3. Protocol**
- 872 S4. R script for comparison of categorical variables
- 873





From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

